Srivastava Chitrangda, Irshad Khushboo, Gupta Yakhlesh, Sarkar Chitra, Suri Ashish, Chattopadhyay Parthaprasad, Sinha Subrata, Chosdol Kunzang
Department of Biochemistry, All India Institute of Medical Sciences, -110029, New Delhi, India.
Present address: Cell Biology, National Institute of Environmental Health Sciences, National Institutes of Health, Durham, NC, 27709, USA.
BMC Cancer. 2020 Jan 28;20(1):62. doi: 10.1186/s12885-019-6435-1.
Overexpression of FAT1 gene and its oncogenic effects have been reported in several cancers. Previously, we have documented upregulation of FAT1 gene in glioblastoma (GBM) tumors which was found to increase the expression of proinflammatory markers, HIF-1α, stemness genes and EMT markers in glioma cells. Here, we reveal NFкB (RelA)/RelA/p65 as the transcriptional regulator of FAT1 gene in GBM cells.
In-silico analysis of FAT1 gene promoter was performed using online bioinformatics tool Promo alggen (Transfac 8.3) to identify putative transcription factor(s) binding motifs. A 4.0 kb FAT1 promoter (- 3220 bp to + 848 bp w.r.t. TSS + 1) was cloned into promoter less pGL3Basic reporter vector. Characterization of FAT1 promoter for transcriptional regulation was performed by in-vitro functional assays using promoter deletion constructs, site directed mutagenesis and ChIP in GBM cells.
Expression levels of NFкB (RelA) and FAT1 were found to be increased and positively correlated in GBM tumors (n = 16), REMBRANDT GBM-database (n = 214) and TCGA GBM-database (n = 153). In addition to glioma, positive correlation between NFкB (RelA) and FAT1 expression was also observed in other tumors like pancreatic, hepatocellular, lung and stomach cancers (data extracted from TCGA tumor data). A 4.0 kb FAT1-promoter-construct [- 3220 bp/+ 848 bp, transcription start site (TSS) + 1, having 17 NFкB (RelA) motifs] showed high FAT1 promoter luciferase-activity in GBM cells (U87MG/A172/U373MG). FAT1 promoter deletion-construct pGL3F1 [- 200 bp/+ 848 bp, with 3-NFкB (RelA)-motifs] showed the highest promoter activity. Exposure of GBM cells to known NFкB (RelA)-activators [severe-hypoxia/TNF-α/ectopic-NFкB (RelA) + IKBK vectors] led to increased pGL3F1-promoter activity and increased endogenous-FAT1 expression. Conversely, siRNA-mediated NFкB (RelA) knockdown led to decreased pGL3F1-promoter activity and decreased endogenous-FAT1 expression. Deletion of NFкB (RelA)-motif at - 90 bp/- 80 bp [pGL3F1δ1-construct] showed significant decrease in promoter activity. Site directed mutagenesis at -90 bp/- 80 bp and ChIP assay for endogenous-NFкB (RelA) confirmed the importance of this motif in FAT1 expression regulation. Significant reduction in the migration, invasion as well as colony forming capacity of the U87MG glioma cells was observed on siRNA-mediated knockdown of NFкB (RelA).
Since FAT1 and NFкB (RelA) are independently known to promote pro-tumorigenic inflammation and upregulate the expression of HIF-1α/EMT/stemness in tumors, targeting the NFкB (RelA)-FAT1 axis may attenuate an important tumor-promoting pathway in GBM. This may also be applicable to other tumors.
FAT1基因的过表达及其致癌作用已在多种癌症中被报道。此前,我们已记录到胶质母细胞瘤(GBM)肿瘤中FAT1基因上调,发现其可增加胶质瘤细胞中促炎标志物、HIF-1α、干性基因和上皮-间质转化(EMT)标志物的表达。在此,我们揭示NFкB(RelA)/RelA/p65是GBM细胞中FAT1基因的转录调节因子。
使用在线生物信息学工具Promo alggen(Transfac 8.3)对FAT1基因启动子进行电子分析,以鉴定假定的转录因子结合基序。将一个4.0 kb的FAT1启动子(相对于转录起始位点(TSS)+1为-3220 bp至+848 bp)克隆到无启动子的pGL3Basic报告载体中。通过使用启动子缺失构建体、定点诱变和GBM细胞中的染色质免疫沉淀(ChIP)进行体外功能测定,对FAT1启动子的转录调节进行表征。
在GBM肿瘤(n = 16)、REMBRANDT GBM数据库(n = 214)和TCGA GBM数据库(n = 153)中,发现NFкB(RelA)和FAT1的表达水平升高且呈正相关。除胶质瘤外,在胰腺癌、肝细胞癌、肺癌和胃癌等其他肿瘤中也观察到NFкB(RelA)与FAT1表达之间呈正相关(数据从TCGA肿瘤数据中提取)。一个4.0 kb的FAT1启动子构建体[-3220 bp/+848 bp,转录起始位点(TSS)+1,具有17个NFкB(RelA)基序]在GBM细胞(U87MG/A172/U373MG)中显示出高FAT1启动子荧光素酶活性。FAT1启动子缺失构建体pGL3F1[-200 bp/+848 bp,具有3个NFкB(RelA)基序]显示出最高的启动子活性。将GBM细胞暴露于已知的NFкB(RelA)激活剂[严重缺氧/TNF-α/异位NFкB(RelA)+IKBK载体]导致pGL3F1启动子活性增加和内源性FAT1表达增加。相反,小干扰RNA(siRNA)介导的NFкB(RelA)敲低导致pGL3F1启动子活性降低和内源性FAT1表达降低。在-90 bp/-80 bp处缺失NFкB(RelA)基序[pGL3F1δ1构建体]显示启动子活性显著降低。在-90 bp/-80 bp处进行定点诱变和对内源性NFкB(RelA)的ChIP分析证实了该基序在FAT1表达调节中的重要性。在siRNA介导的NFкB(RelA)敲低后,观察到U87MG胶质瘤细胞的迁移能力、侵袭能力以及集落形成能力显著降低。
由于已知FAT1和NFкB(RelA)可独立促进肿瘤发生相关炎症,并上调肿瘤中HIF-1α/EMT/干性的表达,靶向NFкB(RelA)-FAT1轴可能减弱GBM中一条重要的肿瘤促进途径。这也可能适用于其他肿瘤。